Cannabinoids and autoimmune diseases: A systematic review

Autoimmunity Reviews

Volumn 15, Issue 6, 2016, Pages 513-528

  Katchan, Valeria ^a,c   David, Paula ^b,c   Shoenfeld, Yehuda ^c,d  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO   (Brazil)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmune diseases; Cannabinoids; Endocannabinoid system; Fibromyalgia; Immunosuppression; Inflammatory bowel disease; Multiple sclerosis; Neuropathic pain; Rheumatoid arthritis; Scleroderma; Tetrahydrocannabinol (THC); Type 1 Diabetes

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; ENDOCANNABINOID; NEUROTRANSMITTER; CANNABINOID;

ABDOMINAL PAIN; APOPTOSIS; APPETITE; AUTOIMMUNE DISEASE; BINDING SITE; CARDIOVASCULAR SYSTEM; CELL MIGRATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CONSTIPATION; CONVULSION; CYTOKINE RELEASE; DIARRHEA; DUODENUM ULCER; DYSPNEA; EATING; FIBROMYALGIA; GASTROENTERITIS; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE; LOWER RESPIRATORY TRACT INFECTION; LUNG EMBOLISM; MACROPHAGE; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NONHUMAN; PLEURA EFFUSION; PNEUMONIA; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMATIC REVIEW; VOMITING; ANIMAL; AUTOIMMUNE DISEASES; INFLAMMATION; MOUSE; NEURALGIA;

ANIMALS; AUTOIMMUNE DISEASES; CANNABINOIDS; HUMANS; INFLAMMATION; MICE; MULTIPLE SCLEROSIS; NEURALGIA;

EID: 84963775522     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.02.008     Document Type: Review

References (270)

1. Pertwee R.G. Pharmacological actions of cannabinoids 2005, 168:1-51. School of Medical Sciences Institute of Medical Sciences, University of Aberdeen, HEP.
2. Howlett C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
3. Pertwee R.G. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006, 147(S1):S163-S171.
4. Di Marzo V. CB1 receptor antagonism: biological basis for metabolic effects. Drug Discov Today 2008, 1-16.
5. Pagotto U., Marsicano G., Cota D., Lutz B., Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev Feb 2006, 27(1):73-100.
6. Howlett A.C. Cannabinoid receptor signaling. Handb Exp Pharmacol 2005, 53-79.
7. Di Marzo V. 'Endocannabinoids'and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1998, 1392:153-175.
8. Giuffrida A., Beltramo M., Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001, 298:7-14.
9. Dinh T.P., Freund T.F., Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 2002, 121:149-158.
10. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997, 74:129-180.
11. Pertwee R.G., Gibson T.M., Stevenson L.A., Ross R.A., Banner W.K., Saha B., et al. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br J Pharmacol 2000, 129:1577-1584.
12. Iversen L. Cannabis and the brain. Brain 2003, 126:1252-1270.
13. Marsicano G., Moosmann B., Hermann H., Lutz B., Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 2002, 80:448-456.
14. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
15. Di Marzo V., Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007, 18:129-140.
16. Hwang S.W., Cho H., Kwak J., Lee S.Y., Kang C.J., Jung J., et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 2000, 97:6155-6160.
17. Ahluwalia J., Urban L., Bevan S., Nagy I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 2003, 17:2611-2618.
18. Price T.J., Patwardhan A., Akopian A.N., Hargreaves K.M., Flores C.M. Modulation of trigeminal sensory neuron activity by the dual cannabinoidvanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol 2004, 141:1118-1130.
19. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sshrgyerd M., Di Marzo V., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.
20. Tognetto M., Amadesi S., Harrison S., Creminon S., Trevisani M., Carreras M., et al. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 2001, 21:1104-1109.
21. Shin J., Cho H., Hwang S.W., Jung J., Shin C.Y., Lee S.Y., et al. Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc Natl Acad Sci U S A 2002, 99:10150-10155.
22. O'Sullivan S.E., Kendall D.A., Randall M.D. Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol 2004, 141:803-812.
23. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005, 5:400-411.
24. Lazzerini P.E., Natale M., Gianchecchi E., et al. Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system. J Mol Med (Berl) 2012, 90:331-342.
25. Pertwee R.G. Inverse agonism at cannabinoid receptors. Inverse Agonism 2003, 75-86. Elsevier, Amsterdam. A.P. IJzerman (Ed.).
26. Pertwee R.G. Novel pharmacological targets for cannabinoids. Curr Neuropharmacol 2004, 2:9-29.
27. Cheer J.F., Cadogan A.-K., Marsden C.A., Fone K.C.F., Kendall D.A. Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 1999, 38:533-541.
28. Barann M., Molderings G., Brss M., Btsnisch H., Urban B.W., Gtsthert M. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 2002, 137:589-596.
29. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995, 73:907-910.
30. Godlewski G., Gtsthert M., Malinowska B. Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold- Jarisch reflex. Br J Pharmacol 2003, 138:767-774.
31. Oz M., Zhang L., Morales M. Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes. Synapse 2002, 46:150-156.
32. Christopoulos A., Wilson K. Interaction of anandamide with the M1 and M4 muscarinic acetylcholine receptors. Brain Res 2001, 915:70-78.
33. Akinshola B.E., Chakrabarti A., Onaivi E.S. In-vitro and in-vivo action of cannabinoids. Neurochem Res 1999, 24:1233-1240.
34. Akinshola B.E., Taylor R.E., Ogunseitan A.B., Onaivi E.S. Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP. Naunyn Schmiedebergs Arch Pharmacol 1999, 360:242-248.
35. De Petrocellis L., Di Marzo V. Review role of endocannabinoids and endovanilloids in Ca2+ signaling. Cell Calcium 2009, 45:611-624.
36. Grotenhermen F. Pharmacology of cannabinoids. Neuroendocrinol Lett 2004, 25(1/2):14-23. Nos.1/2, Feb-Apr.
37. Dewey W.L. Cannabinoid pharmacology. Pharmacol Rev 1986, 38:151-178.
38. Pertwee R. In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. Marijuana/cannabinoids: neurobiology and neurophysiology 1992, 165-218. CRC Press.
39. Baker D., Pryce G., Giovannoni G., Thompson A.J. The therapeutic potential of cannabis. Lancet Neurol 2003, 2:291-298.
40. Domino E.F. Cannabinoids and the cholinergic system. Marihuana and medicine 1999, 223-226. Humana Press.
41. Mattes R.D., Shaw L.M., Engelman K. Effects of cannabinoids (marijuana) on taste intensity and hedonic ratings and salivary flow of adults. Chem Senses 1994, 19:125-140.
42. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995, 73:907-910.
43. Müller-Vahl K.R., Kolbe H., Schneider U., Emrich H.M. Movement disorders. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential 2002, 205-214. Haworth Press.
44. Musty R.E., Paul Consroe P. Spastic disorders. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential 2002, 195-204. Haworth Press.
45. Grundy R.I. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs 2002, 11:1365-1374.
46. A.Hampson Cannabinoids as neuroprotectants against ischemia. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential 2002, 101-110. Haworth Press.
47. Mechoulam R., Shohami E. HU-211: Cannabinoid Neuroprotective Agent. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential 2002, 389-400. Haworth Press. F. Grotenhermen, E. Russo (Eds.).
48. Perez-Reyes M. The psychologic and physiologic effects of active cannabinoids. Marihuana and medicine 1999, 245-252. Humana Press.
49. Tashkin D.P., Levisman J.A., Abbasi A.S., Shapiro B.J., Ellis N.M. Shortterm effects of smoked marihuana on left ventricular function in man. Chest 1977, 72:20-26.
50. Benowitz N.L., Jones R.T. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 1975, 18:287-297.
51. Hollister L.E. Health aspects of cannabis. Pharmacol Rev 1986, 38:1-20.
52. Wagner J.A., Varga K., Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 1998, 76:824-836.
53. Wagner J.A., Jarai Z., Batkai S., Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur J Pharmacol 2001, 423:203-210.
54. Lake K.D., Compton D.R., Varga K., Martin B.R., Kunos G. Cannabinoid induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 1997, 281:1030-1037.
55. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825.
56. Mechoulam R., Shohami E., Fride E., Bab I. The ubiquitous role of endocannabinoids in physiological processes: examples in neuroprotection, feeding and bone formation. First European Workshop on Cannabinoid Research. Madrid (Spain) 2003.
57. Shook J.E., Burks T.F. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989, 249:444-449.
58. McCallum R.W., Soykan I., Sridhar K.R., Ricci D.A., Lange R.C., Plankey M.W. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999, 13:77-80.
59. Murphy L. Hormonal system and reproduction. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential 2002, 289-298. Haworth Press.
60. Pate D. Glaucoma and cannabinoids. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential 2002, 215-224. Haworth Press, (101).
61. Laine K., Jarvinen K., Jarvinen T. Topically administered CB(2)-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits. Life Sci 2003, 72:837-842.
62. Horder J., Cowen P.J., Di Simplicio M., Browning M., Harmer C.J. Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology Jul 2009, 205(1):85-91.
63. Costa B., Vailati S., Colleoni M. SR 141716 A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol 1999, 10:327-331.
64. Arnone M., Maruani J., Chaperon F., Thiebot M.H., Poncelet M., Soubrie P., et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacol 1997, 132:104-106.
65. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998, 63:113-117.
66. Simiand J., Keane M., Keane P.-E., Soubrie P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998, 9:179-181.
67. Berry E.M., Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002, 95:185-190.
68. Bonfá L., Vinagre R.C.O., de Figueiredo N.V. Cannabinoids in chronic pain and palliative care. Rev Bras Anestesiol 2008, 58(3):267-279.
69. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003, 74:486-496.
70. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 2000, 108:169-190.
71. Cabral G.A., Staab A. Effects on the immune system. Handb Exp Pharmacol 2005, 385-423.
72. Pestonjamasp V.K., Burstein S.H. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim Biophys Acta 1998, 1394:249-260.
73. Bisogno T., Maurelli S., Melck D., De Petrocellis L., Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 1997, 272:3315-3323.
74. Lee S.F., Newton C., Widen R., Friedman H., Klein T.W. Differential expression of cannabinoid cb(2) receptor mrna in mouse immune cell subpopulations and following b cell stimulation. Eur J Pharmacol 2001, 423(2-3):235-241.
75. Massa F., Monory K. Endocannabinoids and the gastrointestinal tract. J Endocrinol Invest 2006, 29:47-57.
76. Karsak M., Gaffal E., Date R., Wang-Eckhardt L., Rehnelt J., Petrosino S., et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007, 316:1494-1497.
77. Massa F., Storr M., Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 2005, 83:944-954.
78. Kumar R.N., Chambers W.A., Pertwee R.G. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 2001, 56:1059-1068.
79. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003, 74:486-496.
80. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 2000, 108:169-190.
81. Newton C.A., Klein T.W., Friedman H. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun 1994, 62:4015-4020.
82. Klein T.W., Newton C.A., Nakachi N., Friedman H. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-g, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 2000, 164:6461-6466.
83. Zhu L.X., Sharma S., Stolina M., et al. Delta-9-tetrahydrocan-nabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000, 165:373-380.
84. Yuan M., Kiertscher S.M., Cheng Q., Zoumalan R., Tashkin D.P., Roth M.D. Delta 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T-cells. J Neuroimmunol 2002, 133:124-131.
85. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
86. Thomas B.F., Gilliam A.F., Burch D.F., Roche M.J., Seltzman H.H. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998, 285:285-292.
87. Cunha J.M., Carlini E.A., Pereira A.E., et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21:175-185.
88. Consroe P., Laguna J., Allender J., et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991, 40:701-708.
89. Rieder S.A., Chauhan A., Singh U., Nagarkatti M., Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology August 2010, 215(8):598-605.
90. Schwarz H., Blanco F.J., Lotz M. Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 1994, 55(1):107-115.
91. Maccarrone M., Lorenzon T., Bari M., Melino G., Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 2000, 275(41):31938-31945.
92. Zhu W., Friedman H., Klein T.W. Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of bcl-2 and caspase-1. J Pharmacol Exp Ther 1998, 286(2):1103-1109.
93. McKallip R.J., Lombard C., Martin B.R., Nagarkatti M., Nagarkatti P.S. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther 2002, 302(2):451-465.
94. Lee C.Y., Wey S.P., Liao M.H., Hsu W.L., Wu H.Y., Jan T.R. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and el-4 thymoma cells. Int Immunopharmacol 2008, 8(5):732-740.
95. Klein T.W., Newton C., Zhu W., Daaka Y., Friedman H. Delta 9-tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc Soc Exp Biol Med 1995, 209(3):205-212.
96. Derocq J.M., Segui M., Marchand J., Le Fur G., Casellas P. Cannabinoids enhance human b-cell growth at low nanomolar concentrations. FEBS Lett 1995, 369(2-3):177-182.
97. Derocq J.M., Segui M., Marchand J., Le Fur G., Casellas P. Cannabinoids enhance human b-cell growth at low nanomolar concentrations. FEBS Lett 1995, 369(2-3):177-182.
98. Yebra M., Klein T.W., Friedman H. Delta 9-tetrahydrocannabinol suppresses concanavalin A induced increase in cytoplasmic free calcium in mouse thymocytes. Life Sci 1992, 51(2):151-160.
99. Weiss L., Zeira M., Reich S., Har-Noy M., Mechoulam R., Slavin S., et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006, 39(2):143-151.
100. Watzl B., Scuderi P., Watson R.R. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. Adv Exp Med Biol 1991, 288:63-70.
101. Hollister L.E. Marijuana and immunity. J Psychoactive Drugs 1992, 24:159-164.
102. Zurier R.B. Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 2003, 88:462-466.
103. Cabral G.A., Dove Pettit D.A. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 1998, 83:116-123.
104. De Filippis D., D'Amico A., Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol 2008, 20(1):20-25.
105. Montecucco F., Burger F., Mach F., Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 2008, 294:H1145-H1155.
106. Roth M.D., Baldwin G.C., Tashkin D.P. Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 2002, 121:229-239.
107. Klein T.W., Cabral G.A. Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol 2006, 1:50-64.
108. Raborn E.S., Cabral G.A. Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor. J Pharmacol Exp Ther 2010, 333:319-327.
109. Patinkin D., Milman G., Breuer A., Fride E., Mechoulam R. Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation. Eur J Pharmacol 2008, 595:1-6.
110. Raborn E.S., Marciano-Cabral F., Buckley N.E., Martin B.R., Cabral G.A. The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J Neuroimmune Pharmacol 2008, 3:117-129.
111. Miller A.M., Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 2008, 153:299-308.
112. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003, 23:1398-1405.
113. Sexton M., Silvestroni A., Moller T., Stella N. Differential migratory properties of monocytes isolated from human subjects naïve and non-naïve to cannabis. Inflammopharmacology June 2013, 21(3):253-259.
114. Lu T., Newton C., Perkins I., Friedman H., Klein T.W. Cannabinoid treatment suppresses the t-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J Pharmacol Exp Ther 2006, 319(1):269-276.
115. Hegde V.L., Hegde S., Cravatt B.F., Hofseth L.J., Nagarkatti M., Nagarkatti P.S. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory t cells. Mol Pharmacol 2008, 74(1):20-33.
116. El-Gohary M., Eid M.A. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum Exp Toxicol 2004, 23:149-156.
117. Rachelefsky G.S., Opelz G., Mickey M.R., Lessin P., Kiuchi M., Silverstein M.J., et al. Intact humoral and cell-mediated immunity in chronic marijuana smoking. J Allergy Clin Immunol 1976, 58(4):483-490.
118. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2002, 2:69-82.
119. Correa F., Mestre L., Docagne F., Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 2005, 145:441-448.
120. Gokoh M., Kishimoto S., Oka S., Metani Y., Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. FEBS Lett 2005, 579:6473-6478.
121. Maresz K., Carrier E.J., Ponomarev E.D., Hillard C.J., Dittel B.N. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005, 95:437-445.
122. Cabral G.A., Mishkin E.M. Delta-9-tetrahydrocannabinol inhibits macrophage protein expression in response to bacterial immunomodulators. J Toxicol Environ Health 1989, 26(2):175-182.
123. Lopez-Cepero M., Friedman M., Klein T., Friedman H. Tetrahydrocannabinol-induced suppression of macrophage spreading and phagocytic activity in vitro. J Leukoc Biol 1986, 39(6):679-686.
124. McCoy K.L., Gainey D., Cabral G.A. Delta 9-tetrahydrocannabinol modulates antigen processing by macrophages. J Pharmacol Exp Ther 1995, 273(3):1216-1223.
125. Wang M., Richards A.L., Friedman H., Djeu J.Y. Selective inhibition of natural killer but not natural cytotoxic activity in a cloned cell line by delta-9-tetrahydrocannabinol. J Leukoc Biol 1991, 50:192-197.
126. Pross S., Nakano Y., Smith J., Widen R., Rodriguez A., Newton C., et al. Suppressive effect of tetrahydrocannabinol on specific T cell subpopulations in the thymus. Thymus 1992, 19:97-104.
127. Fischer-Stenger K., Updegrove A.W., Cabral G.A. Delta 9-tetrahydrocannabinol decreases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells. Proc Soc Exp Biol Med 1992, 200:422-430.
128. Samson M.T., Small-Howard A., Shimoda L.M., Koblan-Huberson M., Stokes A.J., Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 2003, 170:4953-4962.
129. Small-Howard A.L., Shimoda L.M., Adra C.N., Turner H. Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem J 2005, 25:25.
130. Ueda Y., Miyagawa N., Wakitani K. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Life Sci 2007, 80:414-419.
131. Pryce G., Ahmed Z., Hankey D.J., Jackson S.J., Croxford J.L., Pocock J.M., et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126(Pt10):2191-2202.
132. Fujiwara M., Egashira N. New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. J Pharmacol Sci 2004, 96(4):362-366.
133. Jackson S.J., Pryce G., Diemel L.T., Cuzner M.L., Baker D. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 2005, 134(1):261-268.
134. Pryce G., Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 2007, 150(4):519-525.
135. Cabranes A., Venderova K., de Lago E., Fezza F., Sanchez A., Mestre L., et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. J Neurobiol Dis 2005, 20(2):207-217.
136. Arevalo-Martin A., Vela J.M., Molina-Holgado E., Borrell J., Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003, 23(7):2511-2516.
137. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49(1):67-79.
138. Ball S., Vickery J., Hobart J., Wright D., Green C., Shearer J., et al. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol Assess 2015, 19. (ISSN 1366-5278).
139. Notcutt LW, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Eur J Pain. May 2009 Mult Scler. 2012 Feb;18(2):219-28.
140. Conte A., CM Bettolo, Onesti E., Frasca V., Iacovelli E., Gilio F., et al. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain May 2009, 13(5). (472-7).
141. Collin C., Davies P., Mutiboko I.K., Ratcliffe S. Sativex spasticity in MS Study Group. randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007 Mar, 14(3):290-296.
142. Goldring M.B., Otero M. Inflammation in osteoarthritis. Curr Rheumatol 2011, 23:471-478.
143. Sumariwalla P.F., Gallily R., Tchilibon S., Fride E., Mechoulam R., Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004, 50:985-998.
144. Zurier R.B., Rossetti R.G., Lane J.H., Goldberg J.M., Hunter S.A., Burstein S.H. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 1998, 41:163-170.
145. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000, 97:9561-9566.
146. Zurier R.B., Rossetti R.G., Burstein S.H., Bidinger B. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol 2003, 65:649-655.
147. Selvi E., Lorenzini S., Garcia-Gonzalez E., Maggio R., Lazzerini P.E., Capecchi P.L., et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin Exp Rheumatol 2008, 26:574-581.
148. Johnson D.R., Stebulis J.A., Rossetti R.G., Burstein S.H., Zurier R.B. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J Cell Biochem 2007, 100:184-190.
149. Mbvundula E.C., Bunning R.A., Rainsford K.D. Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1alphainduced matrix degradation in bovine articular chondrocytes in-vitro. J Pharm Pharmacol 2006, 58:351-358.
150. Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P., Di Marzo V., Elphick M.R., et al. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 2010, 62:588-631.
151. Sun Y., Alexander S.P., Kendall D.A., Bennett A.J. Cannabinoids and PPARalpha signalling. Biochem Soc Trans 2006, 34:1095-1097.
152. O'Sullivan S.E., Kendall D.A. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 2010, 215:611e6.
153. Sumariwalla, Percy F., Gallily Ruth, Tchilibon Susanna Ester; a novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum March 2004, 50(3):985-998.
154. Agarwal N., Pacher P., Tegeder I., Amaya F., Constantin C.E., Brenner G.J., et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007, 10:870-879.
155. Chappell A.S., Desaiah D., Liu-Seifert H., Zhang S., Skljarevski V., Belenkov Y., et al. A double-blind, randomized, placebocontrolled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2001, 11:33-41.
156. Millns P.J., Chapman V., Kendall D.A. Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. Brit J Pharmacol 2001, 132:969-971.
157. Anand U., Otto W.R., Sanchez-Herrera D., Facer P., Yiangou Y., Korchev Y., et al. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008, 138:667-680.
158. Meng I.D., Manning B.H., Martin W.J., Fields H.L. An analgesia circuit activated by cannabinoids. Nature 1998, 395:381-383.
159. Schuelert N., McDougall J.J. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis Rheum 2008, 58:145-153.
160. Richardson D., Pearson R.G., Kurian N., Latif M.L., Garle M.J., Barrett D.A., et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2008, 10:R43.
161. Sagar D.R., Staniaszek L.E., Okine B.N., Woodhams S., Norris L.M., Pearson R.G., et al. Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. Arthritis Rheum 2010, 62:3666-3676.
162. Blake D.R., et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006, 45(1):50-52.
163. Lynch M.E., Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 2011 Nov, 72(5):735-744.
164. Dziadzio M., Smith E., Abraham D.J., et al. Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review. Clin Exp Rheumatol 2004, 22:356-367.
165. Duncan M.R., Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991, 97:686-692.
166. Ellert-Miklaszewska A., Kaminska B., Konarska L. Cannabinoids down-regulate PI3K/akt and Erk signalling pathways and activate proapoptotic function of bad protein. Cell Signal 2005, 17:25-37.
167. Garcia-Gonzalez E, Galeazzi M; Selvi, E. Are cannabinoids able to modulate fibrotic progression in systemic sclerosis? Autoimmunity Reviews 2016, (in press).
168. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005, 5:400-411.
169. Lazzerini P.E., Natale M., Gianchecchi E., et al. Adenosine A2A receptor activation stimulates Collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system. J Mol Med (Berl) 2012, 90:331-342.
170. Gonzalez E.G., Selvi E., Balistreri E., et al. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann Rheum Dis 2012, 71:1545-1551.
171. Atkinson M.A., Leiter E.H. The NOD mouse model of type 1 diabetes: as good as it gets?. Nat Med 1999, 5:601-604.
172. Mandrup-Poulsen T. Beta cell death and protection. Ann N Y Acad Sci 2003, 1005:32-42.
173. Di Marzo V., Piscitelli F., Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol 2011, 203:75-104.
174. Weiss L., Zeira M., Reich S., et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacol 2008, 54:244-249.
175. Satoh J., Takahashi K., Nakazawa T., Sakata Y., Toyota T. Current concept of the pathogenesis of autoimmune type 1 diabetes mellitus. Nippon Rinsho 1999, 57:528-533.
176. Swain S.L. T-cell subsets. Who does the polarizing?. Curr Biol 1995, 5:849-851.
177. Jun H.S., Santamaria P., Lim H.W., Zhang M.L., Yoon J.W. Absolute requirement of macrophages for the development and activation of beta-cell cytotoxic CD8+T-cells in T-cell receptor transgenic NOD mice. Diabetes 1999, 48:34-42.
178. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
179. Skeen M.J., Miller M.A., Shinnick T.M., Ziegler H.K. Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J Immunol 1996, 156:1196-1206.
180. Ohno Y., Aoki N., Nishimura A. In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993, 77:1072-1077.
181. Schicho R., Storr M. Cannabis finds its way into treatment of Crohn's disease. Pharmacology 2014, 93(0):1-3.
182. Izzo A.A., Capasso F., Costagliola A., Bisogno T., Marsicano G., Ligresti A., et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 2003, 125:765-774.
183. Massa F., Marsicano G., Hermann H., Cannich A., et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004, 113:1202-1209.
184. Engel M.A., Kellermann C.A., Burnat G., Hahn E.G., et al. Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis. J Physiol Pharmacol 2010, 61:89-97.
185. Borrelli F., Aviello G., Romano B., Orlando P., et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med (Berl) 2009, 87:1111-1121.
186. Schicho R., Storr M. Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology 2012, 89:149-155.
187. Jamontt J.M., Molleman A., Pertwee R.G., Parsons M.E. The effects of delta-tetrahydrocan-nabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 2010, 160:712-723.
188. Kimball E.S., Schneider C.R., Wallace N.H., Hornby P.J. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 2006, 291:G364-G371.
189. Alhouayek M., Lambert D.M., Delzenne N.M., Cani P.D., et al. Increasing endogenous 2-ara-chidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 2011, 25:2711-2721.
190. Di Sabatino A., Battista N., Biancheri P., Rapino C., Rovedatti L., Astarita G., et al. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol 2011, 4:574-583.
191. Di Carlo G., Izzo A.A. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs 2003, 12(1):39-49.
192. Zalesky A., Solowij N., Yucel M., Lubman D.I., Takagi M., Harding I.H., et al. Effect of long-term cannabis use on axonal fiber connectivity. Brain 2012, 135:2245-2255.
193. Marquéz L., Suárez J., Iglesias M., Bermudez-Silva F.J., de Fonseca F Rodríguez, Andreu M. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One 2009, 4:6893.
194. Wright K., Rooney N., Feeney M., Tate J., Robertson D., Welham M., et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005, 129:437-453.
195. Singh U.P., Singh N.P., Singh B., Price R.L., Nagarkatti M., Nagarkatti P.S. Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol. 2012, 258(2):256-267.
196. Izzo A.A., Sharkey K.A. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010, 126:21-38.
197. Alhouayek M., Muccioli G.G. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med 2012, 18:615-625.
198. Izzo A.A., Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008, 57:1140-1155.
199. Cluny N.L., Keenan C.M., Duncan M., Fox A., Lutz B., Sharkey K.A. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl) methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptors agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. J Pharmacol Exp Ther 2010, 334:973-980.
200. Naftali T., Schleider L.B.L., Dotan I., Lansky E.P., Benjaminov F.S., Konikoff F.M. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin. Gastroenterol. Hepatol. 2013, 11:1276-1280.
201. Lal S., Prasad N., Ryan M., Tangri S., Silverberg M.S., Gordon A., et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011, 23:891-896.
202. Naftali T., Mechulam R., Lev L.B., Konikoff F.M. Cannabis for inflammatory bowel disease. Dig Dis 2014, 32:468-474.
203. Whelan G., Farmer R.G., Fazio V.W., et al. Recurrence after surgery in Crohn's disease. relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology 1985, 88:1826-1833.
204. Naftali T., Lev L.B., Yablekovitz D., Half E., Konikoff F.M. Treatment of Crohn's disease with cannabis: an observational study. IMAJ 2011, 13:455-458.
205. Baker D., Pryce G., Giovannoni G., Thompson A.J. The therapeutic potential of cannabis. Lancet Neurol 2003, 2:291-298.
206. Lahat A., Lang A., Ben-Horin S. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion 2012, 85:1-8.
207. Wilsey B., Marcotte T.D., Deutsch R., Gouaux B., Sakai S., Donaghe H. Low dose vaporized cannabis significantly improves neuropathic pain. J Pain 2013 February, 14(2):136-148.
208. Dworkin R.H., Turk D.C., Walco G.A., Wells C.D., O'Connor A.B., Audette J., et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010, 85:S3-14.
209. Rahn E.J., Hohmann A.G. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 2009, 6:713-737.
210. Lynch M.E. The need for a Canadian pain strategy. Pain Res Manag 2011, 16:77-80.
211. Tang N., Crane C. Suicidality in chronic pain: review of the prevalence, risk factors and psychological links. Psychol Med 2006, 36:575-586.
212. Lynch M, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 72:5: 735-744.
213. Campbell F.A., Tramèr M.R., Carroll D., et al. Are cannabinoids an effective and safe treatment option in the management of pain?. BMJ 2001, 323:1-6.
214. Burstein S.H. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr Pharm Des 2000, 6:1339-1345.
215. Liu J., Li H., Burstein S.H., et al. Activation and binding of peroxisome proliferator-activated receptor γ by synthetic cannabinoid ajulemic acid. Mol Pharmacol 2003, 63:983-992.
216. Burstein S.H., Friderichs E., Kögel B., et al. Analgesic effects of 1',1'dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice. Life Sci 1998, 63:161-168.
217. Karst M., Salim K., Burstein S., Conrad I., Hoy L., Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. A Randomized Controlled Trial JAMA 2003, 290(13):1757-1762.
218. Abrams D.I., Jay C.A., Shade S.B., Vizoso H., Reda H., Press S., et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007, 68:515-521.
219. Ellis R.J., Toperoff W., Vaida F., van den Brande G., Gonzales J., Gouaux B., et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009, 34:672-680.
220. Phillips T.J.C., Cherry C.L., Moss P.J., Rice A.S.C. Painful HIV-associated sensory neuropathy. Pain Clin Updates 2010, XVIII:1-8.
221. Wallace M., Schulteis G., Atkinson J.H., Wolfson T., Lazzaretto D., Bentley H., et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007, 107:785-796.
222. Ware M.A., Wang T., Shapiro S., Robinson A., Ducruet T., Huynh T., et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010, 182(14).
223. Wolfe F. Fibromyalgia: the clinical syndrome. Rheum Dis Clin North Am February 1989, 15(1):1-18.
224. McBeth J., Tomenson B., Chew-Graham C.A., Macfarlane G.J., Jackson J., Littlewood A., et al. Common and unique associated factors for medically unexplained chronic widespread pain and chronic fatigue. J Psychosom Res 2011, 79(6):484-491.
225. 5Z, Basu S., Dittel B.H. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunologic Research 2011, 51(1):26-38.
226. Bohr T. Problems with myofascial pain syndrome and fibromyalgia syndrome. Neurology 1996, 46(3):593-597.
227. Richardson J.D., Aanonsen L., Hargreaves K.M. SR 141716 A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997, 319(2-3):R3-R4.
228. Fiz V.J., Duran M., Capella D., Carbonell J., Farre M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS ONE 2011, 6(4):18440.
229. Ware M.A., Fitzcharles M.A., Joseph L., Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010 Feb 1, 110(2):604-610.
230. Wang T., Collet J.-P., Shapiro S., Ware M.A. Adverse effects of medical cannabinoids: a systematic review. Can Med Assoc J 2008, 178(13):1669-1678.
231. Noyes R., Brunk S.F., Baram D.A., Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975, 15(2-3):139-143.
232. Noyes R., Brunk S.F., Avery D.H., Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975, 18:84-89.
233. Jain A.K., Ryan J.R., McMahon F.G., Smith G. Evaluation of intramuscular levonantradol and plecebo in acute postoperative pain. J Clin Pharmacol 1981, 21:320S-3236.
234. Chang A.E., Shiling D.J., Stillman R.C., et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 1981, 47:1746-1751.
235. Vinciguerra V., Moore T., Brennan E. Inhalation marijuana as an antiemetic for cancer chemotherapy. N Y State J Med 1988, 88(10):525-527.
236. Orr L.E., McKernan J.F., Bloome B. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 1980, 140:1431-1433.
237. Sallan S.E., Cronin C., Zelen M., Zinberg N.E. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980, 302(3):135-138.
238. Steele N., Gralla R.J., Braun D.W., Young C.W. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980, 64(2-3):219-224.
239. Tyson L.B., Gralla R.J., Clark R.A., Kris M.G., Bordin L.A., Bosl G.J. Phase 1 trial of levonantradol in chemotherapy-induced emesis. Am J Clin Oncol 1985, 8(6):528-532.
240. Gorter R. Management of anorexia-cachexia associated with cancer and HIV infection. Oncol Suppl 1991, 5:13-17.
241. Struwe M., Kaempfer S.H., Geiger C.J., et al. Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993, 27(7-8):827-831.
242. Beal J.E., Olson R.L.L., Morales J.O., et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995, 10:89-97.
243. Beal J.E., Olson R., Lefkowitz L., et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997, 14:7-14.
244. National Academy of Science, Institute of Medicine The medical value of marijuana and related substances. Marijuana and Medicine. Assessing the Science Base 1999, National Academy Press.
245. Ungerleider J.T., Andyrsiak T., Fairbanks L., Ellison G.W., Myers L.W. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987, 7(1):39-50.
246. Brady C.M., DasGupta R., Dalton C., Wiseman O.J., Berkley K.J., Fowler C.J. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004, 10(4):425-433.
247. Kunos G., Pacher P. Cannabinoids cool the intestine. Nat Med 2004, 10(7):678-679.
248. Bonfá L., Vinagre R.C.O., de Figueiredo N.V. Cannabinoids in chronic pain and palliative care. Rev Bras Anestesiol 2008, 58(3):267-279.
249. Siegling A., Hofmann H.A., Denzer D. Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 2001, 415:5-7.
250. Julien R.M. A primer of drug action: a concise, nontechnical guide to the actions, uses, and side effects of psychoactive drugs 1997, 548. Henry Holt, New York. 8th ed.
251. Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag 2001, 6:80-91.
252. Cerro J.C. Drogodependencias. Cannabis. Madri, Panamericana 1998, 191-214.
253. a Ed., São Paulo, Atheneu 2006, 361-370.
254. Moreira F.A., Grieb M., Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 2009, 23:133-144.
255. Ghodse A.H. Cannabis psychosis. Br J Addict 1986, 81:473-478.
256. Hall W., Degenhardt L. Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 2008, 7:68-71.
257. Shukla P.C., Moore U.B. Marijuana-induced transient global amnesia. South Med J 2004, 97:782-784.
258. Battistella G., Fornari E., Annoni J.-M., et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology 2014, 39(9):2041-2048.
259. Mayoral M., Calderon H., Cano R., Lombardero M. Allergic rhinoconjunctivitis caused by Cannabis sativa pollen. J Investig Allergol Clin Immunol 2008, 18:73-74.
260. Williams C., Thompstone J., Wilkinson M. Work-related contact urticaria to Cannabis sativa. Contact Dermatitis 2008, 58:62-63.
261. Buchy L., Seidman L.J., Cadenhead K.S., Cannon T.D., Cornblatt B.A., McGlashan T.H., et al. Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis. Psychiatry Res Dec 30, 2015, 230(3):878-884.
262. Grant I., Cahn B.R. Cannabis and endocannabinoid modulators: therapeutic promises and challenges. Clin Neurosci Res 2005, 5(2-4):185-199.
263. El-Gohary M., Eid M.A. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum Exp Toxicol 2004, 23:149-156.
264. Degenhardt L., Hall W.D. The adverse effects of cannabinoids: implications for use of medical marijuana. CMAJ 2008, 178:1685-1686.
265. Hill S., Thomas S.H. Recreational drug toxicity. Clin Med 2008, 8:99-103.
266. Rubino T., Parolaro D. Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 2008, 286:S108-S113.
267. Tashkin D.P. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 2005, 63:93-100.
268. Kaminski N.E. Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. J Neuroimmunol 1998, 83:124-132.
269. Maykut M.O. Health consequences of acute and chronic marihuana use. Prog Neuropsychopharmacol Biol Psychiatry 1985, 9:209-238.
270. Klein T.W., Newton C., Friedman H. Cannabinoid receptors and immunity. Immunol Today 1998, 19:373-381.